© ISTOCK.COM, BBSFERRARI
Italian Institute Revokes Appointment of Cancer Researcher
Italian Institute Revokes Appointment of Cancer Researcher
Pier Paolo Pandolfi left Harvard University last year following allegations of sexual harassment, and has since been accused of research misconduct.
Italian Institute Revokes Appointment of Cancer Researcher
Italian Institute Revokes Appointment of Cancer Researcher

Pier Paolo Pandolfi left Harvard University last year following allegations of sexual harassment, and has since been accused of research misconduct.

Pier Paolo Pandolfi left Harvard University last year following allegations of sexual harassment, and has since been accused of research misconduct.

research integrity
Opinion: Don’t Disparage the Pace of COVID-19 Research
Opinion: Don’t Disparage the Pace of COVID-19 Research
John D. Loike, Salomon Amar | Jun 22, 2020
Fast science—with all its warts—is making unprecedented progress in the fight against COVID-19.
Special Report
Surgisphere Sows Confusion About Another Unproven COVID-19 Drug
Surgisphere Sows Confusion About Another Unproven COVID-19 Drug
Catherine Offord | Jun 16, 2020
The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.
Opinion: Surgisphere Fiasco Highlights Need for Proper QA
Opinion: Surgisphere Fiasco Highlights Need for Proper QA
Nadya Gawadi Heywood, David Long | Jun 12, 2020
Our handbook on best practices for quality assurance in biomedicine can help funding agencies shore up research integrity—which is especially needed at a time when mistakes can have outsize effects.
Surgisphere Fallout Hits African Nonprofit’s COVID-19 Efforts
Surgisphere Fallout Hits African Nonprofit’s COVID-19 Efforts
Catherine Offord | Jun 7, 2020
The company had helped develop a tool to aid decision-making in distributing limited medical equipment among coronavirus patients, but two high-profile retractions call into question the validity of Surgisphere’s work in toto.
<em>Lancet, NEJM </em>Retract Surgisphere Studies on COVID-19 Patients
Lancet, NEJM Retract Surgisphere Studies on COVID-19 Patients
Catherine Offord | Jun 4, 2020
All authors other than company founder and CEO Sapan Desai were “unable to complete an independent audit of the data,” The Lancet states.
Concerns Build Over Surgisphere&rsquo;s COVID-19 Dataset
Concerns Build Over Surgisphere’s COVID-19 Dataset
Catherine Offord | Jun 2, 2020
NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.
When Your Supervisor Is Accused of Research Misconduct
When Your Supervisor Is Accused of Research Misconduct
Katarina Zimmer | Jun 1, 2020
Early career researchers face unique challenges when a senior collaborator becomes embroiled in allegations of scientific malpractice.
Exclusive
Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere
Disputed Hydroxychloroquine Study Brings Scrutiny to Surgisphere
Catherine Offord | May 30, 2020
Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.
US Looks to Block Chinese Grad Students&rsquo; and Researchers&rsquo; Visas
US Looks to Block Chinese Grad Students’ and Researchers’ Visas
Ashley Yeager | May 28, 2020
Administration officials and lawmakers say the move is to shore up national security threats, but university professors argue such cancellations represent targeted discrimination.